Minimally Invasive Surgery and Laparotomy Yield Similar OS in Ovarian Cancer

Video

Minimally invasive surgery for interval debulking resulted in a lower mortality at the 30- and 90-day time points compared with laparotomy in advanced ovarian cancer.

Data indicate that there is no notable difference in survival when using minimally invasive surgery for interval debulking vs laparotomy in patients with advanced ovarian cancer, according to Kirsten Jorgensen, MD.

In an interview with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, Jorgensen, a fellow at The University of Texas MD Anderson Cancer Center, also detailed that despite undergoing more extensive surgery, laparotomy did not provide an additional mortality benefit and that the minimally invasive group was discharged from the hospital faster with a shorter treatment interval.

Moreover, mortality was lower in the minimally invasive group vs the laparotomy group at the 30- and 90-day time points.

Transcript:

The major finding was that there was no worse overall survival for minimally invasive surgery when compared with laparotomy. This also included no worse overall survival at the 5-year estimated overall survival and the overall analysis.

Additionally, we did find that for the laparotomy group, there was more extensive surgery, but this didn’t come with any added mortality benefit. They [also] had higher rates of residual disease. Similar to prior studies, we also found that the minimally invasive group got out of the hospital faster and had shorter treatment time in the hospital.

We did find that there was lower mortality at the 30- and 90-day mark in the minimally invasive group. However, this was a rare outcome overall in both of our groups. Similarly, both groups had low rates of readmission. We were unable to measure complications from surgery directly due to the limitations of the dataset. We are hopeful that this is an avenue for future research, especially prospective research.

Reference

Jorgensen K, Wu FC, Nitecki R, et al. Laparotomy vs minimally invasive surgery for interval debulking surgery among patients with advanced ovarian cancer. Presented at: 2023 Annual Meeting on Women’s Cancer; March 25-28; Tampa, Florida.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content